FDA crackdown triggers 31% Hims selloff, lifts Novo Nordisk shares 2.5%
Novo Nordisk shares jumped 2.5% after the FDA announced plans to pursue legal action against non-approved GLP-1 semaglutide compounds, triggering a 31% plunge in Hims & Hers stock. Novo also filed patent infringement suits seeking permanent bans and damages to protect its Ozempic and Wegovy franchises through 2032.
1. FDA Announces Crackdown on Non-Approved GLP-1 Drugs
The FDA declared plans to pursue legal actions against compounded, non-FDA-approved GLP-1 semaglutide drugs, citing safety and efficacy concerns and warning stakeholders of decisive enforcement steps.
2. Market Reaction: Hims & Hers Plunge and NVO Gain
Following the announcement, Hims & Hers stock plunged 31% intraday while Novo Nordisk shares rallied 2.5%, reflecting investor confidence in Novo’s regulatory-protected weight loss portfolio.
3. Novo Nordisk Files Patent Infringement Lawsuits
Novo filed patent infringement suits against Hims & Hers seeking a permanent injunction and unspecified damages to prohibit the sale of unauthorized semaglutide formulations that bypass FDA review.
4. Implications for Competitive Landscape
These developments reinforce Novo Nordisk’s competitive moat for its Ozempic and Wegovy franchises through patent expiry in 2032 and may deter future knockoff entrants in the booming weight loss market.